Angelo Di Leo
Prato, 59100, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 241 publications
A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2+ PIK3CA-mutated breast cancer.
Journal: Future oncology (London, England)
Published: April 25, 2022
Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 29, 2021
A Serum Metabolomics Classifier Derived from Elderly Patients with Metastatic Colorectal Cancer Predicts Relapse in the Adjuvant Setting.
Journal: Cancers
Published: April 15, 2021
Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis.
Journal: Cancers
Published: February 09, 2021
Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative.
Journal: Cancer discovery
Published: November 11, 2020
Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial.
Journal: Breast cancer research : BCR
Published: October 16, 2020
CDK4/6 inhibitors: A focus on biomarkers of response and post-treatment therapeutic strategies in hormone receptor-positive HER2-negative breast cancer.
Journal: Cancer treatment reviews
Published: October 13, 2020
Heparanase: a potential marker of worse prognosis in estrogen receptor-positive breast cancer.
Journal: NPJ breast cancer
Published: September 15, 2020
Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study.
Journal: Journal of experimental & clinical cancer research : CR
Published: September 04, 2020
The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial.
The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial.
Journal: Scientific reports
Published: August 22, 2020
Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1-98 clinical trial.
Journal: Cancer
Published: August 19, 2020
Last Updated: 09/26/2026